Call for Abstract
Scientific Program
5th International Conference on Alzheimer’s Disease & Dementia, will be organized around the theme “An Insight into Advanced Research and Diagnostic Approaches in Alzheimer’s Disease and Dementia”
Dementia 2016 is comprised of 10 tracks and 106 sessions designed to offer comprehensive sessions that address current issues in Dementia 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Neurological changes in brain
- Track 1-2Genetic associations and susceptibility genes
- Track 1-3Epidemiology and prevalence
- Track 1-4Amyloid protein: A protein of great concern
- Track 1-5Can Alzheimer’s disease be prevented or treated?
- Track 1-6Role of apolipoprotein E
- Track 1-7Age an important factor for Alzheimer’s disease?
- Track 1-8Brain trauma
- Track 1-9Metabolic syndrome and Alzheimer’s disease
- Track 1-10Protein misfolding, aggregation and toxicity
- Track 1-11Disease-causing mutations
- Track 1-12Histone modification, DNA methylation
- Track 1-13Nursing research and Dementia care
- Track 1-14Diabetes induced dementia
- Track 2-1Vascular dementia
- Track 2-2Dementia with lewy bodies
- Track 2-3Fronto-temporal dementia
- Track 2-4Creutzfeldt-Jakob disease
- Track 2-5HIV-related cognitive impairment
- Track 2-6Mild cognitive impairment
- Track 2-7Korsakoffs syndrome
- Track 2-8Rarer causes of dementia
- Track 2-9Stroke Related Dementia
- Track 2-10Traumatic Brain Injury
- Track 2-11Rehabilitation therapy: Dementia
- Track 2-12Rehabilitation therapy: Stroke
- Track 3-1Biomarkers
- Track 3-2Novel approaches in biomarkers
- Track 3-3Living with Alzheimer’s disease
- Track 3-4Patient’s psychological changes
- Track 3-5Neuropathology
- Track 3-6Neuropsychology
- Track 3-7Early detection possibilities
- Track 3-8Different diagnosis procedures
- Track 3-9New methods in diagnosis
- Track 3-10Normal brain aging
- Track 4-1Amyloid and Tau imaging
- Track 4-2Imaging animal models
- Track 4-3Imaging and genetics
- Track 4-4New methods in imaging
- Track 4-5Structural and functional MRI
- Track 4-6Positron emission tomography
- Track 4-7MR spectroscopy
- Track 4-8EEG and brain mapping
- Track 4-9SPECT imaging
- Track 4-10Imaging correlates of clinical, cognitive, and biomarker variables
- Track 5-1Aging
- Track 5-2Prions and Alzheimer’s disease
- Track 5-3Cellular signaling and cell to cell transmission?
- Track 5-4Oxidative damage
- Track 5-5Mitochondrial dysfunction
- Track 5-6Autoimmunity in Alzheimer’s
- Track 5-7Blood-brain barrier and transport
- Track 5-8Neurogenesis and stem cells
- Track 5-9Cell death
- Track 6-1Neurodegenerative diseases
- Track 6-2Geriatric emergency medicine
- Track 6-3Geriatric diagnostics
- Track 6-4Geriatric neurology
- Track 6-5Geriatric oncology
- Track 6-6Geriatric psychiatry or psychogeriatric
- Track 6-7Geriatric pharmacotherapy
- Track 6-8Alcohol addiction and mental health
- Track 6-9Nutritional deficiency
- Track 6-10Preventions: Mental activity and healthy lifestyle
- Track 7-1Amyloid Protein and Alzheimer's Disease
- Track 7-2Amyloid-beta metabolism in Alzheimer's
- Track 7-3Brain accumulation of toxic amyloid β (Aβ)
- Track 7-4Amyloid Plaques & Neurofibrillary Tangles
- Track 7-5Amyloid neuroimaging and biomarkers
- Track 7-6Amyloidosis and Neurodegeneration
- Track 7-7Aβ deposition, cognition and brain volume
- Track 7-8The amyloid hypothesis and potential treatments
- Track 8-1Education and training of medical professionals
- Track 8-2Care and quality of life
- Track 8-3Caregiver support
- Track 8-4Person centered care
- Track 8-5Cognitive training
- Track 8-6Support and training for informal and professional carers
- Track 8-7Putting scientific knowledge into practice
- Track 8-8Non-pharmacological Interventions
- Track 8-9Functional foods
- Track 8-10Art, music & life style
- Track 8-11Nursing and Care Practice
Treatment for Alzheimer's disease is entering a new and exciting phase, with several new drugs beginning clinical trials. Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. There are several different theories underlying the current efforts, and these are briefly reviewed. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area. It is as yet unclear which, if any, of these approaches will be successful, but the high level of activity in each of these three fields provides some hope that an effective treatment for Alzheimer's disease is on the horizon.
- Track 9-1Abeta, truncated and pGlu-Abeta
- Track 9-2Immunotherapy
- Track 9-3Neurotransmitter-based targets
- Track 9-4Anti-oxidants
- Track 9-5Neurotrophic factors
- Track 9-6Protein aggregation
- Track 9-7Deep brain stimulation
- Track 9-8Misfolding and chaperones
- Track 9-9Gene therapy
- Track 9-10Nanotechnology
- Track 9-11Drug-delivery systems
- Track 9-12Anti-inflammatory targets
- Track 10-1Transgenic models
- Track 10-2Pharmacological and lesion models
- Track 10-3Natural and semi natural models
- Track 10-4Primate models
- Track 10-5Zebra fish models
- Track 10-6Animal models of human cognitive aging
- Track 10-7Development of new animal models
- Track 10-8Genetics of translational models
- Track 10-9Protein-protein interactions
- Track 10-10Ethical issues with animal models